Drugs / DAT-2645
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06614751 | Nov 2024 → Nov 2026 expected | breast cancer, colorectal cancer, endometrial cancer, gastric cancer +3 | Danatlas Pharmaceuticals Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07652073 | Jun 2026 → Nov 2027 expected | ovarian cancer | Danatlas Pharmaceuticals Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DAT-2645 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06614751 ↗ |
| Action | Inhibit | “a PARG inhibitor DAT-2645” NCT06614751 ↗ |
| Route | Oral | “Oral administration with 21 days each cycle” NCT07652073 ↗ |
| Target | PARG | “a PARG inhibitor DAT-2645” NCT06614751 ↗ |